| Identification | Back Directory | [Name]
UFP-101 | [CAS]
849024-68-6 | [Synonyms]
UFP-101
PubChem ID: 16152632
[NPHE1, ARG14, LYS15]NOCICEPTIN-NH2
N-(BZL)GLY-GLY-GLY-PHE-THR-GLY-ALA-ARG-LYS-SER-ALA-ARG-LYS-ARG-LYS-ASN-GLN-NH2
N-(Bzl)Gly-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln-NH2 (N-(Bzl)GlyN-Benzylglycine)
L-Glutamamide, N-(phenylmethyl)glycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-asparaginyl- (9CI) | [Molecular Formula]
C82H138N32O21 | [MDL Number]
MFCD04112664 | [MOL File]
849024-68-6.mol | [Molecular Weight]
1908.17 |
| Hazard Information | Back Directory | [Uses]
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect[1][2]. | [in vivo]
UFP-101 elicits a pronounced acute and dosedependent antidepressant-like effect in mice submitted to the forced swimming test (FST)[1]. | [IC 50]
NOP Receptor/ORL1 | [storage]
Store at -20°C | [References]
[1] Calo G, et al. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002;136(2):303-311. DOI:10.1038/sj.bjp.0704706
[2] Gavioli EC, et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci. 2003;17(9):1987-1990. DOI:10.1046/j.1460-9568.2003.02603.x |
|
| Company Name: |
Combio (Suzhou) Ltd.
|
| Telephone: |
17751201929; 17751201929 |
| Website: |
http://www.combiosz.com/ |
|